OCT 5 ~ 2005
510(k) Summary of Safety and Effectiveness for the
MED flash II Intense Pulsed Light System KO S| SOY
_
This 5]0(k) Summary of Safety and Effectiveness is being submitted in accordance with
the requirements of the SMDA 1990 and 21 CFR 807.92.
1. General Information
Submitter: General Project S.r.1.
Via della Gora 15/19
50025 Montespertoli
Firenze, Italy
Contact Person: Maureen O’Connell
5 Timber Lane
North Reading, MA 01864
Telephone: 978-207-1245
Fax: 978-207-1246
Summary Preparation Date: June 1, 2005
2. Names
Device Name: MED flash II Intense Pulsed Light System
Classification Name: Laser Instrument, Surgical Powered
Product Code: GEX
Panel: Dermatology and Plastic Surgery
3. Predicate Devices
The MED flash II Intense Pulsed Light System is substantially equivalent to a
combination of the following devices: Palomar’s StarLux V (K041086,
K033549), Palomar’s EsteLux V (K040081), Palomar’s EsteLux G (K020941),
Lumenis’ IPL Quantum SR and the Real Time Chiller (K020839), Novalis
Medical’s Clareon Pulsed Light System (K043319), Cutera’s Optional Pulsed
Light Hand Piece Family (K050047), Cynosure’s Photosilk and Photosilk Plus
(K041095) and General Project’s Flash 1 (K022583).
4. Device Description
The MED flash IT Intense Pulsed Light System is a medical device emitting light
radiation in the range from 590 nm to 1200 nm. The system is based on a quick
power discharge of capacitors in a Xenon lamp, mounted on a handpiece. This
generates a rapid and Intense Pulsed Light.
coo 11

The Med flash JI system contains five principal components:
e Charge system of the capacitors
e Electronic control system
e Control panel
e Handpiece with exchangeable lamp box
e Handpiece cooling system

5. Indications for Use
The MED flash II Intense Pulsed Light System which is generally indicated for
use in:

e¢ Removal of unwanted hair from all skin types and to effect stable long-term or
permanent, hair reduction

e Treatment of inflammatory acne (acne vulgaris)

e Treatment of benign pigmented epidermal and cutaneous lesions including warts,
scars, striae, lentigines, nevi, melasma and café-au-lait

e Treatment of vascular lesions, including port wine stains, hemangiomas,
angiomas, telangiectasias, rosacca, facial and leg veins

¢ The integrated cooling handpiece is intended to provide pre-cooling of the
epidermis, to reduce thermal injury to the epidermis, and to reduce patient pain, &
discomfort associated with light applications.

6. Performance Data
None presented.

v50 12

é 4 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
ook Food and Drug Administration
9200 Corporate Boulevard
OCT 5 ~ 2005 Rockville MD 20850
General Project $.r.1.
c/o Ms. Maureen O’Connell
Regulatory Consultant
5 Timber Lane
North Reading, Massachusetts 01864
Re: K051508
Trade/Device Name: MED flash II Intense Pulsed Light System
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and plastic
surgery and in dermatology
Regulatory Class: Il
Product Code: GEX
Dated: August 25, 2005
Received: August 26, 2005
Dear Ms. O’Connell:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug.
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration. listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class II (Special Controls) or class IH] (PMA). it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements. including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as sct
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2- Ms. Maureen O’Connell
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled,
"Misbranding by reference to premarket notification” (21CFR Part 807.97). You may obtain
other general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(301) 443-6597 or at its Internet address http:/Avww.fda.gov/edrh/dsma/dsmamain. html

Sincerely yours,

CHerbine Pmedad

Mark N. Melkerson

Acting Director

Division of General, Restorative

and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Number (if known)
Device Name MED flash I Intense Pulsed Light System
Indications for Use:
The MED flash II Intense Pulsed Light System is indicated for use in:
e Removal of unwanted hair from all skin types and to effect stable long-term or
permanent, hair reduction
e Treatment of inflammatory acne (acne vulgaris)
e Treatment of benign pigmented epidermal and cutaneous lesions including warts,
scars, striae, lentigines, nevi, melasma and café-au-lait
e Treatment of vascular lesions, including port wine stains, hemangiomas,
angiomas, telangiectasias, rosacea, facial and leg veins
e The integrated cooling handpiece is intended to provide pre-cooling of the
epidermis, to reduce thermal injury to the epidermis, and to reduce patient pain, &
discomfort associated with light applications.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE
IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use OR Over The Counter Use
(Per 21 CFR 801.109)
(Optional Format 1-2-96)
f \ ro
, t . f 5
hub orve Awahar(Division Sign‘Off)
Division of General, Restorative,
and Neurological Devices
S1SO%
510(k) Number_KO> *>— 0

